argenx Unveils Ambitious 2026 Strategic Priorities to Advance Vision 2030

argenx SE, a global immunology company focused on improving the lives of people with severe autoimmune diseases, has released its preliminary 2025 financial results and outlined its strategic priorities for 2026. The company reported strong growth with approximately $4.15 billion in full-year 2025 global product net sales, a 90 % year‑over‑year increase, supported by $1.29 billion in fourth‑quarter sales. The impact of its lead medicine, VYVGART, continues to expand, with roughly 19,000 patients currently on treatment, and the potential launch for AChR‑Ab seronegative generalized myasthenia gravis (gMG) expected by the end of 2026 if approved. Looking ahead, argenx has defined three strategic priorities for 2026 to accelerate progress toward its Vision 2030 goals—which include treating 50,000 patients worldwide, securing 10 labeled indications, and advancing five pipeline candidates into Phase 3 development. These priorities are: expanding global patient impact with VYVGART, advancing the long‑term future of FcRn‑targeted medicines, and delivering the next wave of immunology innovation. The company also anticipates four major registrational readouts in 2026, including the first for empasiprubart, and plans to bring three new molecules into Phase 1, contributing to a total of 10 clinical‑stage molecules by year‑end. #argenx #VYVGART #Vision2030 #ImmunologyInnovation #SlimScan #GrowthStocks #CANSLIM